Opinion|Videos|July 3, 2024
Educating Patients on Complications Associated with CAR T-Cell Therapy
The panel provides clinical insights on talking with patients about complications associated with CAR T-cell therapy.
Advertisement
Episodes in this series
- Dr Park: What protocols and processes do you have in place at the community practice to continue monitoring and managing potential long-term complications or adverse events associated with CAR T-cell therapy?
- How do you approach monitoring for and managing late-onset neurotoxicity or other long-term adverse effects that may occur after the patient transitions back to the community setting?
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.
Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
3
Why Caregivers Are Critical During Bispecific Step-Up Dosing
4
Prizlon-cel Earns FDA RMAT and Fast Track Designations in Relapsed LBCL
5